Other
Combination Therapy
0
Pipeline Programs↗
40
Active Trials↗
38
Companies Involved↗
Combination Therapy is an early-stage landscape with 0 programs across 38 companies. The most active players are Novartis, Vertex Pharmaceuticals, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
222
clinical trials
Completed118 · 53%
Unknown status42 · 19%
Recruiting19 · 9%
Terminated15 · 7%
Not yet recruiting15 · 7%
Withdrawn7 · 3%
Other6 · 3%
Clinical Trials
Trial Activity
222 trials
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07330050·31 enrolled
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Recruiting·—·N/A·NCT06457477·50 enrolled
Comparison of Sequential to Initial Combination Therapy in PAH
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06968962·376 enrolled
Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile Spasm
Recruiting·—·N/A·NCT04302116·250 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)